 A general schema for 3 potential dose levels to be pursued on the 4-days-on, 3-days-off AZD5363 schedule Schedule A and 2-days-on, 5-days-off AZD5363 schedule Schedule B in Part A of the study are listed below. The starting dose of olaparib will be fixed at 300mg bd in both schedules. These schema only provide general guidance; it will be possible for doses of one or both drugs to be escalated or de-escalated in a seesaw fashion contingent on the toxicity andor PKPD data reported. This may create dose cohort combinations not listed below. Both PK and PD data will be taken into consideration if available. With the exception of dose level 1, actual dose escalationde-escalation will be determined following a discussion with the SRC during dose escalation teleconferences. Dose escalation will continue until MTDs are reached. Patients will be dosed on a flat scale and not by body weight or body surface area. Both schedules will be carried out in parallel. 